Pune-based SII is to submit an updated safety data of phase 2 and 3 clinical trials in India, immunogenicity data from the clinical trial in the UK and India, as well as the assessment results of the UK Medicines and Healthcare products Regulatory Agency
With arrangements being made to possibly commence with inoculations starting next month in India, the drug regulator of the country is considering the vaccine candidate of Oxford University to initiate the vaccination drive.
Before deciding to give the green light for emergency use authorisation to the vaccine being manufactured by the Serum Institute of India (SII), the Central Drugs Standard Control Organisation (CDSCO) is waiting for the UK to give the nod to the vaccine first.
Once the UK drug regulator gives its approval, which sources are expecting for to be sometime next week, the COVID-19 expert committee at the CDSCO will take over the proceedings for the country. The department is to hold a meeting to thoroughly review the clinical evaluations to ascertain the safety and immunogenicity standards of the vaccine before granting it emergency use authorisation, said official sources from the clinical evaluations conducted abroad and in India before granting any emergency authorisation for the vaccine here, official sources told PTI.
While Pfizer, whose vaccine candidate with German partner BioNtech has been granted approval for emergency use in over ten countries, the American pharma is yet to make a presentation in India. As far as the indigenous 'Covaxin' that is being manufactured by Bharat Biotech is concerned, emergency approval could take even more time owing to the fact that phase 3 clinical trials are still underway.
"Going by this, Oxford vaccine 'Covishield' is likely to be the first to be rolled out in India," said a source.
Last week, SII had submitted some additional requisite data to the Drug Controller General of India, added the sources. Earlier this month, SII and Bharat Biotech along with Pfizer had applied Pfizer had applied to the Drugs Controller General of India (DCGI) for emergency use authorisation for their vaccines. While the subject expert committee (SEC) on COVID-19 at CDSCO had asked for the former two companies for additional efficacy and safety data, Pfizer's application was not upheld as the company had asked for more time to come up with a presentation for the committee.
Amid fears about the mutated variant of SARS-CoV-2 detected in the UK, government officials recently said that it will have no impact on the potential of emerging vaccines that are being developed in India and other countries.
Pune-based SII is to submit an updated safety data of phase 2 and 3 clinical trials in India, immunogenicity data from the clinical trial in the UK and India, as well as the assessment results of the UK Medicines and Healthcare products Regulatory Agency (MHRA).
About Hyderabad-based Bharat Biotech, the SEC recommended that " the firm should present the safety and efficacy data from the ongoing phase 3 clinical trial in the country for further consideration."
Serum Institute of India happens to be the world's largest manufacturer of vaccines, and its collaboration with the University of Oxford and Astrazeneca has already led to 40 million doses being produced in the country.
Source - Business Today
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
SII CEO Adar Poonawalla & Director Prakash Kumar Singh call on Hon'ble President of India Smt. Droupadi Murmu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.